News

  1. Nine New Analyses Show Novartis' LCZ696 Could Change Course Of Heart Failure For Patients 11/18/2014

    New data on Novartis’ investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF) shows it has the potential to change the course of the disease for patients.1,2 In August 2014, Novartis presented topline results from the landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor enalapril on key endpoints, including significantly reducing the risk of cardiovascular (CV) death or heart failure hospitalization.5

  2. Isis Initiates Phase 1 Study Of ISIS-APOA Rx To Treat Atherosclerosis 4/3/2013

     Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.

  3. Catabasis Initiates Phase 1 Trial Of CAT-2003 For Treatment Of Severe Hypertriglyceridemia 3/26/2013

    Catabasis Pharmaceuticals Inc., today announced the initiation of a Phase 1 study to investigate the safety and tolerability of CAT-2003 in healthy volunteers and in adults with mildly elevated lipids. CAT-2003 is a conjugate of niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, covalently linked using the company's proprietary SMART Linker technology to create a new chemical entity and is being developed for patients with severe hypertriglyceridemia.

  4. Piramal Enterprises' Diagnostic Division Launches QDx Instacheck 3/19/2013

    Piramal Enterprises’ diagnostic division recently announced the launch of “QDx Instacheck” Right-here-Right-now.

  5. CeQur Announces Positive Results From Study Evaluating Simple Insulin Delivery Device Among People With Type 2 Diabetes 2/28/2013

    CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that initial data from a study of the company's PaQ® Insulin Delivery Device were presented today at the 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France.

  6. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation 2/26/2013

     Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-CRPRx in patients with paroxysmal atrial fibrillation.

  7. Gains In Cardiac Rhythm Management Devices Offset By Lower Pricing 2/6/2013

    The rising incidence of lifestyle diseases such as diabetes and obesity, an ageing population and the prevalence of cardiovascular diseases such as arrhythmia, heart failure and atrial fibrillation, have expanded the patient pool for cardiac rhythm management (CRM) devices in both Europe and the United States. 

  8. Portola And Lee's Pharmaceutical Enter Into Agreement To Expand Phase 3 APEX Study Of Betrixaban Into China 1/29/2013

    Portola Pharmaceuticals, Inc. and Lee's Pharmaceutical (HK) Ltd. (HKSE: 0950) today announced an agreement to jointly expand the Phase 3 APEX study of betrixaban into China, with an option for Lee's to negotiate for the commercial rights to the drug in China.

  9. DiaMedica Successfully Completes DM-199 cGMP Manufacturing And Pre-Clinical Toxicology Safety Studies 1/29/2013

    DiaMedica (TSX VENTURE:DMA) has successfully completed cGMP manufacturing of DM-199 to be utilized in upcoming clinical trials.

  10. ActiGraph Launches ActiLife Mobile App 1/14/2013

    ActiGraph, a leading provider of objective patient monitoring solutions for the global research community, recently announced the release of a new mobile app for researchers.